Kornimate/medical-research-clean huggingface dataset:
enhancing life quality in community-dwelling older omanis by telling their life story

Conditions: Healthy Older Adults

Summary: this study investigates whether sharing life stories and creating life-story books can enhance the quality of life and life satisfaction and reduce depression in older adults. the primary research question is: did the quality of life, life satisfaction, and levels of depression improve more for participants in the intervention group compared to those in the control group? participants will be divided into two groups: * intervention group: these participants will share life stories and create life-story books. * control group: these participants will not share life stories or create life-story books.

background: the main goal of this study is to investigate whether telling their life stories and developing a life-story book intervention affects a group of omani older adults' quality of life, life satisfaction, and depression symptoms. methods: in oman, a randomized controlled trial with repeated measures was conducted to evaluate the impact of the intervention. 75 older individuals were randomly assigned to either the intervention group (n = 38) or the control group (n = 37). baseline demographic data were collected as an initial reference point. to comprehensively assess changes over time, participants' depression levels, life satisfaction, and overall quality of life were measured at multiple time points: weeks 1, 2, 3, 4, and 8. this longitudinal design allowed for a nuanced analysis of intervention effects across different implementation phases. this study believes that participants in the 8-week trial of the life-story review intervention were successful in reducing depression and improving life satisfaction and quality of life in the older population. healthcare professionals can use such interventions to enhance older persons' mental health and well-being.

Eligibility criteria:
inclusion criteria: * aged 60-90; * depressive symptoms score between 5 and 10; * able to sign the consent form; * able to speak arabic or english; * able to communicate without the need for a hearing aid. exclusion criteria: * using hypnotics, sedatives, antidepressants, anticholinergics, antihistamines, tranquilizers, or melatonin for sleep; * having a medical diagnosis of parkinson's, dementia, alzheimer's disease, or a serious mental problem; * participants assigned to the intervention group who did not want to be audio recorded.

Keywords: depression life satifaction quality of life older adults
lexiscan(tm) rb-82 myocardial perfusion pet: a comparison with dipyridamole stress

Conditions: Coronary Artery Disease

Summary: lexiscan(tm) has ideal properties for rb-82 pet imaging and the stress response it invokes may offer multiple advantages for the diagnosis of coronary disease and functional abnormalities. the goal of this investigation is to establish quantitative equivalence of lexiscan(tm) rest/stress rb-82 pet images to dipyridamole rest/stress images.


Eligibility criteria:
inclusion criteria: * bmi \<35 * no intervention or change in management between dipyridamole and lexiscan(tm) pet exclusion criteria: * bmi \>35 * an intervention or change in management between dipyridamole and lexiscan(tm) pet

Keywords: lexiscan(tm) dipyridamole myocardial perfusion positron emission computed tomography
ascending multiple-doses of erenumab (amg 334) in healthy adults and in migraine patients

Conditions: Migraine

Summary: the primary purpose of this study is to determine whether erenumab is safe and well tolerated in healthy adults and migraine patients. as part of the secondary objectives, this study will be conducted to characterize the pharmacokinetic (pk) profile of erenumab after multiple subcutaneous (sc) doses in healthy adults and migraine patients, as well as to characterize the effect of erenumab on the capsaicin induced increase in dermal blood flow after multiple sc doses in healthy adults and migraine patients.


Eligibility criteria:
inclusion criteria: healthy male and female subjects, as well as male or female subjects with migraines between 18 and 55 years of age, inclusive, with no history or evidence of clinically relevant medical disorders as determined by the investigator in consultation with the amgen physician; exclusion criteria: - history or evidence of clinically significant disorder (including psychiatric), condition or disease that, in the opinion of the investigator or amgen physician would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion;

Keywords: migraine
use of probiotic yogurt in obese women

Conditions: Obesity; Dysbioses

Summary: this study aimed to examine the effects of using probiotic yogurt on body components (body weight, height, etc.) and digestive system (distention, gas, etc.) in obesity (obese women), which is an important public health problem all over the world.

obesity is an important public health problem worldwide and is associated with non-communicable diseases such as type 2 diabetes, hypertension, coronary heart disease, hyperlipidemia, non-alcoholic fatty liver, some neoplasms, and infertility disease.however, it is supported by the literature that nutrition and obesity cause microbial dysbiosis. in this study, it was aimed to use probiotics and yogurt with the thought that nutrition can manipulate the microbiota. it was aimed to investigate the effects of probiotic yogurt consumption on anthropometric measurements, metabolic parameters, and gastrointestinal symptoms in obese women (25-45 years old) with the prospective method. the study was carried out in patients who were diagnosed with obesity by the doctor, consulted the dietitian, and accepted + signed the voluntary consent form. total data and measurements were followed and recorded by the same dietitian. compliance with medical nutrition therapy, recording of scales were followed weekly.patients diagnosed with covid-19 during the study were excluded from the study.

Eligibility criteria:
inclusion criteria: * female patients aged 25-45 years, with a bmi of 27-35 kg/m2 diagnosed as obese by the doctor * female patients without a chronic disease * female patients between the ages of 25-45 with regular menstrual cycles, * female patients between the ages of 25-45 who are not pregnant or lactating * female patients who do not use drugs, herbal products, etc. nutritional supplements. exclusion criteria: * patients with bmi≥ 36 kg/m2 * patients with diabetes, gastrointestinal diseases, crf, etc. * women in pregnancy and lactation period, * male patients * weight loss medicine etc. patients with drug use * patients who use antibiotics * patients using probiotics, propolis, herbal products, etc. * patients with menstrual irregularity * female patients who have entered the menopause
effectiveness of circular muscle exercise (paula method) versus kegel exercise for urinary stress incontinence

Conditions: Urinary Stress Incontinence (SI)

Summary: this is a randomized controlled trial comparing two methods of exercise for the treatment of stress incontinence ( loss of urine after physical exertion) in women. we are comparing the paula method of circular muscle exercise, in which circular muscles controlling sphincters of the body (such as the eyes, mouth and rectum) are exercised, with pelvic floor training (kegel exercises) in women in the community. the study hypothesis is that the effectiveness of circular muscle exercises is equivalent to pelvic floor training among women with this disorder.

background: urinary stress incontinence(si) is defined as involuntary urinary loss which appears during increased intra-abdominal pressure which can be measured objectively. it is an important social and hygienic problem. its prevalence varies fron 12-55% depending on age, and geography. the economic costs of this condition were estimated to reach 24 billion dollars in the us in 1995. the objectives of this study are to evaluate two non-invasive methods of treatment of stress incontinence. methods: 200 women who chosen from the community and suffering from si will enter the study and will be randomized to one of two arms. the first arm is the paula method of circular muscle exercises: these women will receive private lessons from a registered paula instructor. the system is based on activating circular muscles in the body. the second arm will receive instruction in pelvic floor muscle training by a physiotherapist. the clinical trial will compare the efficacy of the methods for the treatment of si. the candidates for inclusion in the trial will undergo a gynecological exam and a "pad test". the efficacy will be measured in terms of changes in the pad test (quantity of urinary leakage) and subjective reports of the participants on leakage, quality of life and sexual function.

Eligibility criteria:
inclusion criteria:ambulatory women, aged 20-65, living in jerusalem area, able to understand instruction in hebrew or english, suffering from urinary stress incontinence with a positive pad test of at least 1 gm - exclusion criteria:pregnant,within 12 weeks of delivery,6 weeks since abortion,breastfeeding, illnesses which limit physical activity (cardiac, respiratory, psychiatric and neurological), pad test \< 1gm,pelvic surgery within last 6 months, genital prolapse grade 3 or higher, previous surgery for urinary incontinence, previous pelvic radiation therapy -

Keywords: urinary stress incontinence randomized trial circular muscle training pelvic floor training bioequivalence
timing and intrauterine insemination in unexplained infertility

Conditions: Intrauterine Insemination

Summary: to determine the most suitable time for administration of (human chorionic gonadotropin )hcg prior to intrauterine insemination (iui) to optimize pregnancy outcome and to have the best success rates so the cases divided in to four groups according to the time of hcg administration .

iui with or without ovarian stimulation is a common treatment for infertility ,it is a simple procedure the semen is prepared in the laboratory and transferred by a catheter and injected intrauterine .ultrasound folliculometry is used for monitoring follicular growth where some clinicians prefer the natural cycles and others prefer ovarian stimulation and human chorionic gonadotropin (hcg)trigger for better timing .so cases will take induction and folliculometry will be done until the follicle reach 18mm trigger with hcg .women will be randomly divided to four groups .the first group will undergo iui at 24 after trigger the second iui at36 hour after trigger the thirdg at 48 after trigger and finaly the last group iui will be done simultaneos with trigger the out come the number of pregnant women for each group.

Eligibility criteria:
inclusion criteria: * mild male infertility or unexplained infertility exclusion criteria: * adanced male factor endometriosis uterine abnormality sever semen parameters i impairment according to who 2010 non ovulatory cycles bilatral tubal block

Keywords: infertility
the effect of pudendal blocks on voiding dysfunction following slings

Conditions: Stress Urinary Incontinence

Summary: to determine the effect of a bilateral pudendal block on voiding dysfunction following midurethral slings.

midurethral slings (mus) are commonly performed to treat stress urinary incontinence in women. one common complication is short-term postoperative voiding dysfunction. approximately 20% of patients undergoing mus have difficulty voiding in the immediate postoperative period and are discharged home with an indwelling bladder catheter. a pudendal block provides analgesia to the vulva, vagina, and perineum and is used in various fields, ranging from obstetrical indications to hemorrhoidectomies. the colorectal literature has demonstrated an improvement in postoperative voiding dysfunction with intraoperative bilateral pudendal blockade, presumably due to pain relief. however, only one study has explored the effect of a pudendal blockade on postoperative voiding in patients undergoing mus. this was a small french case series of 9 patients, and it concluded that it was a safe procedure with good patient satisfaction. given the scant literature evaluating voiding dysfunction following pudendal blocks in mus, and the encouraging data from anorectal surgeries, we aim to study this effect via a randomized, placebo-controlled, double-blinded trial.

Eligibility criteria:
inclusion criteria: * women undergoing a midurethral sling without concomitant procedures under general anesthesia exclusion criteria: * unable to consent (lacking capacity) * under 18 years of age * pregnant women * prisoners * using intermittent self-catheterization preoperatively * neurological disease or spinal cord injury resulting in voiding dysfunction * allergy to bupivacaine * diagnosis of chronic pain syndromes * daily use of narcotics * intra-operative bladder injury necessitating use of a prolonged indwelling foley catheter
gore excluder® endoprosthesis - low permeability in treatment of abdominal aortic aneurysms

Conditions: Aortic Aneurysm, Abdominal

Summary: the purpose of this study is to evaluate the performance of the gore excluder® bifurcated endoprosthesis-low permeability in the primary treatment of infrarenal abdominal aortic aneurysms.


Eligibility criteria:
inclusion criteria: 1. infrarenal abdominal aortic aneurysms less than 4.5 cm in diameter 2. anatomy meets excluder bifurcated endoprosthesis - low permeability specification criteria per instructions for use 3. access vessel able to receive 18 french introducer sheath 4. life expectancy \> 2 years 5. appropriate candidate for endovascular repair 6. ability to comply with protocol requirements including follow-up 7. 21 years of age or older, male or infertile female\*\* exclusion criteria: 1. mycotic or ruptured aneurysm 2. participating in another investigational device or drug study within one year 3. documented history of drug abuse within six months 4. myocardial infarction or cerebral vascular accident within six weeks 5. pulmonary insufficiency requiring chronic home oxygen or inability to ambulate due to pulmonary function 6. iliac anatomy that would require occlusion of both internal iliac arteries 7. planned occlusion or reimplantation of significant mesenteric or renal arteries 8. planned concomitant surgical procedure or previous major surgery within 30 days 9. previous prosthesis placement in the aorta or iliac arteries 10. degenerative connective tissue disease (e.g., marfan's and ehlers danlos syndrome)
determination of the safety and effectiveness of an oral rinse in the reduction of medication associated metallic taste

Conditions: Medication Associated Metallic Taste , Dysgeusia

Summary: patients taking chemotherapeutic agents often do not comply well with their dosing regiment since many of these medications cause a metallic taste in the mouth. the primary intent is to determine the effectiveness of the oral rinse in reducing the metallic taste in the mouth associated with various chemotherapeutic agents. this clinical study a randomized, double-blind, single-treatment, parallel design with a placebo as the control. the duration of the trial will be 1 month.


Eligibility criteria:
inclusion criteria: 1. subject has read, signed and received a copy of the informed consent and hipaa authorization prior to study initiation. 2. subject is able to follow verbal and/or written instructions, perform oral hygiene procedures and return to the test facility for specified study examinations. 3. subject is between the ages of 18 and 75 years inclusive. 4. subject will not have professional cleaning during the 3-month trial. 5. subject has no history of allergy to personal care consumer products, or their ingredients, relevant to any ingredient in the test drug, as determined by the principal investigator. 6. subject has a minimum of 16 natural teeth and a complaint of moderate to severe medication associated metallic taste. 7. subject agrees to refrain from the use of any oral rinse, toothpaste or dentifrice other than the colgate® cavity protection fluoride toothpaste and study rinse provided on visit 1 for the duration of the study. 8. subject agrees to refrain from the use of other oral care products not supplied by the study center 9. subject agrees to be compliant with study procedures. 10. females of childbearing potential agree to use an adequate method of birth control and agree to pregnancy testing at the first and second visit. exclusion criteria: 1. subject has a condition that requires prophylactic antibiotics for dental examinations and treatments (e.g., has a history of valvular heart disease or a recently placed prosthetic joint). 2. subject has disqualifying acute or chronic medical illness as judged by the principal investigator. 3. subject is currently taking phenytoin, cyclosporin, nifedipine or any other drug that has been shown to cause gingival enlargement or affect the gingivae. 4. subject has taken antibiotics, steroids, or non-steroidal anti-inflammatory drugs (e.g., aspirin, ibuprofen) within one week prior to baseline examination. subjects taking long-term aspirin (81 mg/day) may be included in the trial, but subjects taking a larger dose will be excluded. subjects taking blood thinners such as coumadin (warfarin), lovenox, or plavix will be excluded. 5. subject is pregnant (based on pregnancy result) or lactating.
bactiseal catheter safety registry in china

Conditions: Hydrocephalus

Summary: research purpose: this study aimed to continue to evaluate safety information from subjects implanted with a catheter (trade name: bactiseal) produced by codman \& shurtleff, inc. of the united states. device safety would be assessed based on all the adverse events that occurred within one year after the subjects implanted the catheter.

this study aimed to continue to evaluate safety information from subjects implanted with a catheter (trade name: bactiseal) produced by codman \& shurtleff, inc. of the united states. device safety would be assessed based on all the adverse events that occurred within one year after the subjects implanted the catheter. this study was designed to be single arm, multi-center, and retrospective. a total of 50 patients would be retrospectively enrolled. information would be collected on adverse events of subjects enrolled within one year after the implantation of the bactiseal catheter from august 07, 2018 to novemver 30, 2020. the following information would be collected from subjects' medical records or hospitals' databases (if any): 1. general condition of the subjects 2. intraoperative condition and catheter implantation 3. information on the shunt product 4. adverse events of subjects within one year after the operation and classification of the adverse events 5. relevant examinations in case of postoperative infection 6. other adverse event-related information (except anticipated adverse events)

Eligibility criteria:
inclusion criteria: * the informed consent was exempted by the ethics committee of a research center. either a subject or his/her legal representative signed the informed consent form (icf) prior to enrollment. * a subject had an indication suitable to use bactiseal catheter. * a subject received a hydrocephalus shunt at least one year ago. exclusion criteria: * a subject didn't have an indication suitable to use the product. * a subject was known to be allergic to a component or ingredient of the product to be implanted, including silicone tubing, rifampicin, and clindamycin. * according to the comprehensive judgment of an investigator, a subject had an infection of the implant site when the shunt was implanted, such as ventriculitis, meningitis, peritonitis, and local implant skin infection. * a subject was simultaneously implanted with another shunt system different from bactiseal catheter. * a subject had a contraindication of the shunt operation. * a subject had uncorrected coagulopathy or any bleeding disorder.

Keywords: hydrocephalus shunt infection
safety and efficacy study of endobarrier in subjects with type ii diabetes and obesity

Conditions: Type II Diabetes

Summary: the purpose of this study is to evaluate the safety and efficacy of a second generation endobarrier liner compared to a study diet to treat subjects with type 2 diabetes. this is a randomized, controlled study which will enroll approximately 70 subjects with type 2 diabetes. randomization will be one to one with approximately 35 endobarrier device subjects and approximately 35 study diet subjects. subjects randomized as diet subjects will be offered the endobarrier device after 12 months on study at the investigator's discretion if treatment of the device subjects indicates adequate efficacy. this study will be conducted at three (3) investigational sites. the primary efficacy endpoint is: * assessment of the percent (%) of subjects who achieve a ≥ 0.5% reduction in hba1c at 24 weeks or last visit from baseline between the two groups. secondary endpoints are: * percent (%) of subjects who achieve a hba1c of 7.0% or lower at week 24 or last visit from baseline. * percent (%) of subjects who have their diabetic medication(s) dosage decreased or discontinued at week 24 or last visit from baseline. * percent (%) of subjects who achieve a decrease in post-prandial excursions as evidenced by challenge to a standardized meal tolerance test (mtt) at week 24 or last visit from baseline. * assessment of absolute weight loss (kg) at week 24 or last visit from baseline. * percent (%) of subjects who maintain a hba1c lower than their baseline assessment at 12 months. * compare physical component summary (pcs), mental component summary (mcs) and quality adjusted life years (qalys)via analysis of the sf-36v2 qol.

utilization of the endobarrier gastrointestinal liner in obese subjects with t2dm demonstrated an acceptable safety profile with clinically significant improvements in glycemic control and body weight when compared to a similar diet controlled group of subjects.

Eligibility criteria:
inclusion criteria: * age \> 18 years and \< 65 years * male or female * subjects with type 2 diabetes who have been treated for ≤10 years * bmi\> 30 - \< 50 * subjects with an hba1c level \> 7.5 and ≤ 10.0% * subjects taking a combination of metformin and sulfonylureas and/or insulin (other than pre-mixed long and short acting insulins, ie. novomix 30) * patients willing to comply with study requirements * patients who have signed an informed consent form exclusion criteria: * subjects taking oral medications to control their diabetes other than sulfonylureas and metformin * subjects diagnosed with type 1 diabetes mellitus or having a history of ketoacidosis * subjects on insulin \> 10 years * subjects requiring insulin \> 70 units per day * subjects on pre-mixed insulin (ie. novomix 30)

Keywords: type ii diabetes obesity